Laura Chico
Stock Analyst at Wedbush
(2.24)
# 2,656
Out of 4,876 analysts
224
Total ratings
36.67%
Success rate
-1.53%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $17 → $15 | $3.04 | +393.42% | 2 | Jun 24, 2025 | |
| LEN Lennar | Reiterates: Neutral | $130 | $111.54 | +16.55% | 1 | Jun 18, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $121 | $127.35 | -4.99% | 17 | Jun 12, 2025 | |
| PHVS Pharvaris | Reiterates: Outperform | $27 | $17.17 | +57.25% | 6 | Jun 5, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Neutral | $13 → $8 | $7.94 | +0.76% | 11 | May 22, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $30 | $15.08 | +98.94% | 11 | May 16, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.24 | +222.58% | 5 | May 16, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $18 → $17 | $4.79 | +254.91% | 2 | May 16, 2025 | |
| JBIO Jade Biosciences | Reiterates: Outperform | $17 | $9.72 | +74.90% | 2 | May 15, 2025 | |
| ANRO Alto Neuroscience | Reiterates: Neutral | $4 | $2.39 | +67.36% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $14.39 | +108.48% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $22.89 | +13.59% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $43.76 | -36.01% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $13.23 | +225.02% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $16.80 | +155.95% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.33 | +795.79% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $18.08 | +99.12% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $5.61 | +399.11% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $18.05 | +60.66% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $9.28 | -35.31% | 9 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $147 | $126.83 | +15.90% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 → $48 | $36.59 | +31.20% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.22 | +883.61% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $32.42 | +51.14% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $2.95 | +137.69% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.70 | +197.70% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $14.68 | +186.10% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $12.07 | +40.85% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.35 | +3,051.86% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $3.75 | +33.51% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $54.72 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.44 | +104.92% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $14.48 | +925.91% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $7.94 | +8,968.12% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $48.47 | +477.74% | 1 | Apr 21, 2017 |
Larimar Therapeutics
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.04
Upside: +393.42%
Lennar
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $111.54
Upside: +16.55%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $127.35
Upside: -4.99%
Pharvaris
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $17.17
Upside: +57.25%
Vigil Neuroscience
May 22, 2025
Downgrades: Neutral
Price Target: $13 → $8
Current: $7.94
Upside: +0.76%
Travere Therapeutics
May 16, 2025
Reiterates: Outperform
Price Target: $30
Current: $15.08
Upside: +98.94%
Gossamer Bio
May 16, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.24
Upside: +222.58%
Solid Biosciences
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $4.79
Upside: +254.91%
Jade Biosciences
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $9.72
Upside: +74.90%
Alto Neuroscience
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.39
Upside: +67.36%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.39
Upside: +108.48%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $22.89
Upside: +13.59%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $43.76
Upside: -36.01%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $13.23
Upside: +225.02%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $16.80
Upside: +155.95%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.33
Upside: +795.79%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $18.08
Upside: +99.12%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $5.61
Upside: +399.11%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $18.05
Upside: +60.66%
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $9.28
Upside: -35.31%
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $126.83
Upside: +15.90%
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $36.59
Upside: +31.20%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.22
Upside: +883.61%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $32.42
Upside: +51.14%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $2.95
Upside: +137.69%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.70
Upside: +197.70%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $14.68
Upside: +186.10%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $12.07
Upside: +40.85%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.35
Upside: +3,051.86%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.75
Upside: +33.51%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $54.72
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.44
Upside: +104.92%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $14.48
Upside: +925.91%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $7.94
Upside: +8,968.12%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $48.47
Upside: +477.74%